All News

A recent study sought to develop a robust predictive model for patients whose disease will transform into acute myeloid leukemia, a complication that is associated with a poor prognosis.

While President Trump's State of the Union address is not finalized, he may plan to unveil a promise to end HIV transmission in America by 2030; a federal judge dismissed a lawsuit brought by Maryland that claimed the Trump administration is failing to enforce the Affordable Care Act; new cystic fibrosis (CF) treatments targeting the genetic mutations that cause the disease help about 90% of patients, meaning that 10% are still waiting for a cutting-edge therapy.

A program designed to schedule follow-up appointments with primary care practices within 7 days of hospital discharge was associated with fewer readmissions.

According to a recent study, the out-of-pocket clinical costs and capitalized clinical costs per approved drug were both lower for orphan drugs compared with nonorphan drugs.

In 2015, the Neulasta On-Body Injector (OBI) Onpro device was introduced as a less costly method of pegfilgrastim administration. While the device has been found to be safe in healthy volunteers and have pharmacokinetics similar to that of traditional pegfilgrastim, there have been limited data comparing the 2 methods.

Abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition looked at how monitoring minimal residual disease can help predict outcomes in acute myeloid leukemia (AML).

Long noncoding RNAs (lncRNAs) are involved in the pathogenesis of b-cell precursor acute lymphoblastic leukemia (BCP-ALL) and contribute to the stratification of BCP-ALL subtypes, according to results from a recent study.

A recent review outlined a vast array of biomarkers that may have clinical implications on the treatment and prognosis of colorectal cancer (CRC).

A recent study using the 2016 genome-wide association study (GWAS) identified that vascular mechanisms, but also neuronal and metal ion homeostasis, may play a role in migraine susceptibility.

February 1 is Go Red for Women Day, a campaign that aims to raise awareness of heart disease and stroke as one of the leading killers of women. Here are 5 things about women’s heart health.

When the American College of Cardiology/American Heart Association (ACC/AHA) released new cholesterol guidelines in 2013, replacing older guidelines and changing statin eligibility, more patients with HIV became recommended for statin therapy. However, many patients are still not recommended for or prescribed the treatment.

A recent study sought to compare several available oral immunotherapies for the treatment of relapsing-remitting multiple sclerosis (MS).

Establishing competition between insurance companies is believed to be the most effective way to lower the total cost of premiums, explains a new issue brief from The Commonwealth Fund.

This week, the top managed care news included House and Senate hearings on the cost of prescription drugs; a study finding patients with diabetes can be safely switched to cheaper insulin; and the first non-chemotherapy combination being approved for the treatment of chronic lymphocytic leukemia.

Senator Mitt Romney, R-Utah, warned PhRMA that he and his new colleagues are working to tackle the issue of high prescription drug prices; Kentucky is delaying the start of work requirement rules for a portion of its Medicaid population; despite its approval by the FDA last year, Teva’s generic version of an epinephrine autoinjector is not available at the largest pharmacies or through drug distributors.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

HHS Secretary Alex Azar proposed Thursday to end drug rebates in Medicare Part D and in Medicaid managed care plans and treat them as kickbacks, in a move that could have implications for private plans as well. The rule was announced in the same week as hearings on Capitol Hill about drug pricing, especially the rising cost of insulin.

Stroke-related health risks of giving birth are highlighted in 2 posters that will be presented at the American Stroke Association's International Stroke Conference 2019, being held February 6-9, 2019, in Honolulu, Hawaii.

A critical obstacle to chronic disease management is that the patients most likely to benefit from primary care aren’t necessarily the patients who see their providers. Digital health helps providers support patients outside the traditional 4 walls of the doctor’s office.

Among older patients with non-Hodgkin lymphoma receiving myelosuppressive chemotherapy, use of primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) increased significantly over the past 20 years.

A recent report from the Government Accountability Office (GAO) found that claims costs and federal and state policies largely influenced insurer participation in exchanges during the early years of the Affordable Care Act (ACA).

Elderly adults suffering function and cognitive impairment who are in need of long-term services and support (LTSS) often endure substantial out-of-pocket expenses since LTSS is not covered by Medicare.

Reflecting on a year of breakthrough advancements in the treatment of rare, difficult to treat cancers, the American Society of Clinical Oncology (ASCO) has named “Progress in Treating Rare Cancers” as the Advance of the Year.

CMS is expanding how Medicare Advantage (MA) can offer supplemental health benefits for the 2020 plan year, it said Thursday as it also announced the rate adjustment for the private plans that participate in the program.

Here are the top 5 articles for the month of January.

A new study has demonstrated that e-cigarettes are more effective for smoking cessation than nicotine; the Department of Veterans Affairs released a proposal that would expand private healthcare access for veterans; and Aetna and Apple have launched a health app that helps users personalize and achieve their health goals.

Javed Butler, MD, MPH, MBA, discusses the 2018 American College of Cardiology Expert Consensus Decision Pathway, which includes guidance on the use of SGLT2 inhibitors and GLP-1 receptor agonists, and its potential to change the treatment paradigm for patients with type 2 diabetes.

Sephin1 provided protective benefits that delayed loss of myelin and onset of debilitating disease in mouse models of multiple sclerosis.